Small molecule · Inhibitor of coagulation factor Xa (F10) and thrombin (coagulation factor IIa) (F2) · developed by Leo Pharma As
Tinzaparin is a low molecular weight heparin obtained by enzymatic depolymerization of porcine intestinal heparin. It acts mainly through antithrombin to inhibit coagulation factors Xa and IIa (thrombin), and it is studied in deep venous thrombosis and pulmonary embolism.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 24, 2017). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01828697 | Phase 4 | Deep Venous Thrombosis | Completed | ASPE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Deep Venous ThrombosisPulmonary Embolism
Updated Nov 8, 2026.